



PATENT
Customer No. 22,852
Attorney Docket No. 6854-11

RECEIVED
AUG 14 2002
TCS CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Tadashi Mukai et al.) Group Art Unit: 1614
Serial No.: 09/555,026) Examiner: Donna A. Jogoe
Filed: January 18, 2002)
For: Cilostazol Preparation)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE

In response to the restriction requirement of July 17, 2002, applicants elect Group I and claims 1-14 and 20-26 for further prosecution in this application. While the Examiner only referred to claims "20-25," since claim 26 is dependent on claim 21, it is presumed he meant to refer to claims "20-26," particularly since claim 26 is not a part of Groups II or III.

Applicants reserve the rights to file a divisional application on non-elected claims 15-19 and 27-28.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 13, 2002

By: 

Arthur S. Garrett
Reg. No. 20,338

395469_1.DOC

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com